Hui-Ju Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hui-Ju Han has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hao Yu
Fudan University School of Medicine, Shanghai, China
2 shared publications - Jian-Wei Liu
Wuhan University School of Health Sciences, Wuhan, Hubei, China
2 shared publications - Xue-Jie Yu
State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, Hubei, China
2 shared publications - Chuan-Min Zhou
Wuhan University School of Health Sciences, Wuhan, Hubei, China
1 shared publication - Hongling Wen
Department of Health Inspection and Quarantine, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
1 shared publication - Li-Jun Wang
State Key Laboratory of Virology, School of Health Sciences, Wuhan University, Wuhan 430071, China
1 shared publication
Latest Publications
- 1 May 2019
- Published by Elsevier in Acta Tropica
- Vol. 193, 124-128
Trypanosoma dionisii in insectivorous bats from northern China
- 1 May 2019
- Published by Elsevier in Acta Tropica
- Vol. 193, 124-128
Trypanosoma dionisii in insectivorous bats from northern China
- Open Access
Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
Since emerging in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been a global public health threat with a high fatality rate and worldwide distribution. There are no approved vaccines or therapies for MERS until now. Passive immunotherapy with neutralizing monoclonal antibodies (mAbs) is an effective prophylactic and therapeutic reagent against emerging viruses. In this article, we review current advances in neutralizing mAbs against MERS-CoV. The receptor-binding domain (RBD) in the spike protein of MERS-CoV is a major target, and mouse, camel, or human-derived neutralizing mAbs targeting RBD have been developed. A major problem with neutralizing mAb therapy is mutant escape under selective pressure, which can be solved by combination of neutralizing mAbs targeting different epitopes. Neutralizing mAbs are currently under preclinical evaluation, and they are promising candidate therapeutic agents against MERS-CoV infection.
Open AccessNeutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
Since emerging in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been a global public health threat with a high fatality rate and worldwide distribution. There are no approved vaccines or therapies for MERS until now. Passive immunotherapy with neutralizing monoclonal antibodies (mAbs) is an effective prophylactic and therapeutic reagent against emerging viruses. In this article, we review current advances in neutralizing mAbs against MERS-CoV. The receptor-binding domain (RBD) in the spike protein of MERS-CoV is a major target, and mouse, camel, or human-derived neutralizing mAbs targeting RBD have been developed. A major problem with neutralizing mAb therapy is mutant escape under selective pressure, which can be solved by combination of neutralizing mAbs targeting different epitopes. Neutralizing mAbs are currently under preclinical evaluation, and they are promising candidate therapeutic agents against MERS-CoV infection.